MaxCyte launches CHANGE-seq-BE and ONE-seq-BE assays
MaxCyte (NASDAQ: MXCT) announces the launch of CHANGE-seq-BE and ONE-seq-BE off-target nomination assays through its SeQure service for adenine and cytosine base editors.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
MaxCyte (MXCT) launches CHANGE-seq-BE and ONE-seq-BE off-target tools
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ aimed at strengthening off-target assessment for genome editing therapies.